Please login to the form below

Not currently logged in
Email:
Password:

Targovax appoints Oystein Soug as CEO

CFO takes on top role as Gunnar Gårdemyr steps down

Targovax Oystein SougNorwegian immuno-oncology specialist Targovax has appointed Oystein Soug as its new chief executive officer following the resignation of Gunnar Gåardemyr.

Formerly chief financial officer, Soug joined Targovax in 2015 bringing over 20 years of financial management experience to the role.

He has previously served as chief financial officer for Algeta, a Norwegian oncology biotech that was bought by Bayer in 2014, and spent six years at Orkla, a Norwegian consumer goods company.

Jónas Einarsson, chairman of Targovax's board of directors, said: “We are delighted to announce the appointment of Oystein as the new chief executive officer of Targovax.

“He has played a key role as chief financial officer over the past year - successfully guiding us on the path to becoming a publicly-listed company, securing funding for further development of the company's ongoing and planned trials.

“We are confident in his ability to lead the company as we approach important milestones in 2017 and 2018 in our innovative clinical pipeline designed to help the patient's own immune system fight cancer.”

16th November 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Quintiles Medical Communications

Quintiles’ award-winning medical communications group sits at the heart of the enterprise. We offer a range of innovative strategic services,...

Latest intelligence

Australian Flu and the dilemma of naming diseases
...
Wearables and Healthcare
What place do wearables have in affecting actual patient health outcomes and can they contribute to the NHS’s sustainability agenda? Or are they just the latest fad?...
What does a future-proof rep look like?
Businesses can no longer afford to push ahead with the traditional Key Account Management model....

Infographics